نتایج جستجو برای: high dose cytarabine

تعداد نتایج: 2292508  

Journal: :The hematology journal : the official journal of the European Haematology Association 2004
Thomas Prébet Sophie Ducastelle Stephan Debotton Aspasia Stamatoullas Eric Deconinck Christophe Fruchart Nicole Gratecos Norbert Ifrah François Dreyfus Pierre Fenaux Eric Wattel

Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination chemotherapy associating fludarabine, mitoxantrone (MXN), and high-dose cytarabine (continuous infusi...

2009
Mona Meyer Daniela Rübsamen Robert Slany Thomas Illmer Kathleen Stabla Petra Roth Thorsten Stiewe Martin Eilers Andreas Neubauer

Acute myeloid leukemia (AML) is a clonal disease originating from myeloid progenitor cells with a heterogeneous genetic background. High-dose cytarabine is used as the standard consolidation chemotherapy. Oncogenic RAS mutations are frequently observed in AML, and are associated with beneficial response to cytarabine. Why AML-patients with oncogenic RAS benefit most from high-dose cytarabine po...

Journal: :AJNR. American journal of neuroradiology 1993
D J Vaughn J G Jarvik D Hackney S Peters E A Stadtmauer

The authors report an acute cerebral and cerebellar syndrome in a patient treated with high-dose cytarabine. Diffuse high-intensity lesions in the central white matter on T2-weighted MR completely reversed with resolution of the clinical syndrome. Although the autopsy revealed cerebellar injury, the cerebral cortex was grossly and microscopically normal, consistent with a reversible process.

Journal: :Blood 1999
T Büchner W Hiddemann B Wörmann H Löffler W Gassmann T Haferlach C Fonatsch D Haase C Schoch D Hossfeld E Lengfelder C Aul A Heyll G Maschmeyer W D Ludwig M C Sauerland A Heinecke

Early intensification of chemotherapy with high-dose cytarabine either in the postremission or remission induction phase has recently been shown to improve long-term relapse-free survival (RFS) in patients with acute myeloid leukemia (AML). Comparable results have been produced with the double induction strategy. The present trial evaluated the contribution of high-dose versus standard-dose cyt...

2015
Linu A. Jacob S. Aparna K. C. Lakshmaiah D. Lokanatha Govind Babu Suresh Babu Sandhya Appachu

Introduction. The incidence of Acute Myeloid Leukemia (AML) increases progressively with age and its treatment is challenging. This prospective case control study was undertaken to compare the safety, efficacy, and cost-effectiveness of decitabine with those of cytarabine in older patients with newly diagnosed AML who are not fit for intensive chemotherapy. Materials and Methods. 30 eligible pa...

2009
Sung Jin Hong Jin Seok Kim Jong Hee Chang Kyoung Min Kim Soo Jeong Kim Hye Won Lee June-Won Cheong Seung Tae Lee Yoo Hong Min

The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet been identified because of the heterogeneity of the therapies employed and the lack of large, prospective clinical trials. We describe a 46-year-old relapsed PCNSL patient who was successfully treated wi...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Judith E Karp Brian M Thomas Jacqueline M Greer Christopher Sorge Steven D Gore Keith W Pratz B Douglas Smith Karen S Flatten Kevin Peterson Paula Schneider Karen Mackey Tomoko Freshwater Mark J Levis Michael A McDevitt Hetty E Carraway Douglas E Gladstone Margaret M Showel Sabine Loechner David A Parry Jo Ann Horowitz Randi Isaacs Scott H Kaufmann

PURPOSE Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine cytotoxicity in acute leukemia cell lines and leukemic blasts in vitro. To extend these findings ...

2015
Xiang-Sheng Li Wei-Long Yang Fa-Zheng Shen Guo-Jun Gao Ji-Wei Ma Bao-Zhe Jin

OBJECTIVE To evaluate the short-term therapeutic effects of low-dose cytarabine plus surgical resection on elderly patients with trigeminal nerve tumor and to observe the safety. METHODS A total of 120 elderly patients with trigeminal nerve tumor were divided into a treatment group and a control group by random draw (n=60), and both groups were subjected to resection by stereotactic image-gui...

Journal: :Blood 2005
Kenneth F Bradstock Jane P Matthews Raymond M Lowenthal Heather Baxter John Catalano Timothy Brighton Devinder Gill Paul Eliadis Douglas Joshua Paul Cannell Anthony P Schwarer Simon Durrant Anne Gillett Jerry Koutts Kerry Taylor John Bashford Christopher Arthur Arno Enno Lindsay Dunlop Jeff Szer Michael Leahy Surender Juneja Graham A R Young

The value of administering sequential courses of chemotherapy containing high-dose cytarabine in both induction and consolidation therapy for acute myeloid leukemia (AML) has not been assessed in a prospective randomized trial. Two hundred ninety-two AML patients aged 15 to 60 years were enrolled in the Australasian Leukaemia and Lymphoma Group (ALLG) AML trial number 7 (M7) protocol to evaluat...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید